Anne Phillips, M.D., has been appointed as Novo Nordisk's as vice president, Clinical Development, Medical and Regulatory Affairs for North America. Dr. Phillips reports directly to Jerzy Gruhn, president, Novo Nordisk Inc., the company's U.S. affiliate, and senior vice president for Novo Nordisk A/S North America. She will serve as a member of the U.S. executive team.

Dr. Phillips brings more than 20 years of medical, research, and regulatory experience to her new role. She'll be leading the North American clinical
development and medical affairs activities across the diabetes and biopharmaceutical franchises, as well as regulatory affairs and medical operations.

Dr. Phillips comes to Novo Nordisk from GlaxoSmithKline, where she worked within the company's Research and Development organization since 1998. She served initially as a medical adviser, and advanced into leadership roles, most recently as vice president, Medicine Development Leader within GSK's Oncology R&D organization. Between 2005 and 2009, Dr. Phillips headed a global team which supported Phase II-IV activities in the metabolic clinical area and provided leadership into development of all GSK metabolic and cardiovascular molecules and assets.

Dr. Phillips received her medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada.

She replaces Dr. Per Falk, who was promoted to senior vice president for Novo Nordisk's Biopharmaceuticals Research Unit in Denmark.